Results 31 to 40 of about 10,503 (191)

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

open access: yes, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny   +6 more
core   +1 more source

Nanoparticles in the treatment of chronic lung diseases [PDF]

open access: yes, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G   +9 more
core   +2 more sources

Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE) [PDF]

open access: yes, 2022
Background: Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation.
Baraldi F.   +13 more
core   +1 more source

Update on Biological Therapeutics for Asthma [PDF]

open access: yes, 2010
: Asthma poses a significant burden on patients, families, health care providers, and the medical system. While efforts to standardize care through guidelines have expanded, difficulty in managing severe asthma has encouraged research about its ...
Bruce S. Bochner, Marisha L. Cook
core   +1 more source

Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma

open access: yesBMJ Case Reports, 2020
Recent years have seen an increase in use of mepolizumab and other biological therapies for the treatment of severe eosinophilic asthma. A few cases of paradoxical responses to mepolizumab therapy have now been reported and are hypothesised as being a response to immune complex formation.
Raquel Despiney   +2 more
openaire   +3 more sources

Corticosteroids: still at the frontline in asthma treatment? [PDF]

open access: yes, 2012
Inhaled corticosteroids (ICS) have led to improved asthma control and reduced asthma mortality in the Western world. ICS are effective in combating T-helper type 2-driven inflammation featuring mast cell and eosinophilic airway infiltration. Their effect
Barnes, Peter J.   +2 more
core   +1 more source

Severe Pediatric Asthma Therapy: Mepolizumab

open access: yesFrontiers in Pediatrics, 2022
There is a growing need for advanced treatment in children with persistent and severe asthma symptoms. As a matter of fact, between 2 and 5% of asthmatic children experience repeated hospitalizations and poor quality of life despite optimized treatment with inhaled glucocorticoid plus a second controller.
Nicola Ullmann   +8 more
openaire   +3 more sources

Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]

open access: yes, 2017
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe   +4 more
core   +3 more sources

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]

open access: yes, 2014
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard   +4 more
core   +4 more sources

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]

open access: yes, 2017
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy   +4 more
core   +3 more sources

Home - About - Disclaimer - Privacy